Clinical Trials Directory

Trials / Completed

CompletedNCT00374101

High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding

Proton Pump Inhibitors in Conjunction to Endoscopic Therapy for Bleeding Peptic Ulcers: a Randomized Clinical Trial of High vs Standard Doses

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
450 (planned)
Sponsor
Casa Sollievo della Sofferenza IRCCS · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

High intravenous dosage of Proton Pump Inhibitors is not better than standard dosage in bleeding peptic ulcers successfully treated by endoscopic therapy

Detailed description

The recent Canadian consensus conference on the management of patients with non-variceal upper gastrointestinal bleeding recommends a high regimen of PPIs, consisting in a dosage of 80-mg bolus followed by the 8 mg/H infusion, as being superior to the standard dosage (40 mg twice daily by bolus injection) in conjunction with some type of endoscopic therapy. However, by pooling data fromm studies comparing high doses of PPIs as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. As the previous conclusion became apparent in a meta-analytical evaluation of only 2 randomized clinical trials, more studies are needed on this topic.

Conditions

Interventions

TypeNameDescription
DRUGomeprazole
DRUGpantoprazole

Timeline

Start date
2005-01-01
Completion
2007-03-01
First posted
2006-09-08
Last updated
2007-04-05

Locations

10 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT00374101. Inclusion in this directory is not an endorsement.